Tests anti-CD7 CAR-T cells in T-cell leukemia or lymphoma that returned
Tests donor-derived CAR-T cells targeting CD7 in people whose T-cell leukemia or lymphoma returned.
Key facts
- Who runs it
- Stephan Grupp MD PhD
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Registry title
- Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
- Status
- Active, not recruiting
- Phase
- Phase 1
- People taking part
- 33 people, planned
- Started
- 29 Apr 2025
- Expected to end
- 30 May 2031
- Type of study
- Interventional, 2 groups
- Treatments tested
- Allogeneic anti-CD7 CAR-T cells (BEAM-201)
- Record updated
- 13 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young adults with T-cell acute lymphoblastic leukemia or lymphoma that came back or did not respond to treatment, and whose cancer cells carry CD7.
- Age
- 0 to 29 years
- Sex
- All sexes
- Disease stage
- T-ALL or T-LLy in second or later relapse, first relapse after a transplant, or disease that did not respond to chemotherapy.
- Earlier treatment
- Must be able to have strong chemotherapy and an allogeneic stem-cell transplant, with a donor found. Must not have had earlier CD7-targeted therapy.
- Biomarker or test result
- At least 90% of the cancer cells must be positive for CD7 (by flow cytometry or immunohistochemistry).
Main reasons for not taking part
- Active hepatitis B or C, active HTLV infection, or HIV infection
- Uncontrolled infection
- Prior CD7-targeted therapy
- Stem-cell transplant within 90 days, or active graft-versus-host disease needing steroids
- Pregnant or breastfeeding
The registry criteria, word for word
Show all 30 criteriaShow less
Other criteria
- Patients must meet all the following criteria to be eligible for enrollment into the study:
- Patients (ages ≥ 18 years) or parent/legal guardians (for patients ages < 18 years) must provide signed, written informed consent according to local IRB and institutional requirements
- Ages 0 to 29 years
- T-ALL/T-LLy in second or greater relapse, first relapse post-transplant, or chemotherapy-refractory disease. Specifically:; Second or greater relapse or post-transplant relapse, defined as:; BM with ≥ 5% lymphoblasts by morphologic assessment or evidence of extramedullary disease after second documented CR; OR; Flow cytometric confirmation of relapsed T-ALL of at least 0.1% after second CR documented to have been MRD negative < 0.1%; OR; Any detectable relapsed disease post-allogeneic HSCT with flow cytometric confirmation of T-ALL of at least 0.1%; OR; Biopsy confirmed evidence of relapsed T-LLy after second CR; OR; Any detectable disease post-allogeneic transplant with biopsy confirmed evidence of T-LLy; Refractory disease, defined as:; Primary refractory T-ALL or T-LLy, defined as failure to achieve CR after induction chemotherapy, per investigator assessment and based on biopsy-or MRD-confirmed evidence of residual T-ALL or T-LLy; OR; Relapsed, refractory disease, defined as > 0.1 % MRD or morphologic evidence of disease or evidence of residual T-LLy after 1 course of re-induction chemotherapy for patients who have relapsed after previously achieving a CR NOTE: Patients with mixed phenotype acute leukemia with T cell dominant phenotype may be enrolled if the aforementioned criteria are met
- Documentation of CD7 expression on leukemic or T-LLy blasts (defined as at least 90% of blasts positive for CD7 by flow cytometry or immunohistochemistry)
- Patients with prior or current history of CNS3 disease will be eligible if CNS disease is responsive to therapy
- Eligible for myeloablative conditioning for and allogeneic HSCT based on the investigator's assessment with an available donor identified by a FACT accredited transplant center
- Lansky Performance Status (ages < 16 years at time of consent) or Karnofsky Performance Status (KPS) (ages ≥ 16 years at time of consent) score of ≥ 50
- Patients of childbearing potential must have a negative urine or serum pregnancy test at screening
- Adequate organ function defined as:; Adequate Serum creatinine based on age/gender; ALT ≤ 5x ULN in the absence of ALL infiltration of the liver; Bilirubin ≤ 3 × ULN for age Note: ALT and/or bilirubin results that exceed this range are acceptable if, in the opinion of the physician-investigator (or as confirmed by liver biopsy), the abnormalities are directly related to ALL infiltration of the liver; Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and <Grade 3 hypoxia; DLCO ≥40% (corrected for anemia if necessary) if PFTs are clinically appropriate as determined by the investigator; Cardiac echocardiography (ECHO) with left ventricular shortening fraction (LVSF) ≥ 30% or left ventricular ejection fraction (LVEF) ≥ 50%. In cases where quantitative assessment of LVSF/LVEF is not possible, a statement by the cardiologist that the ECHO shows qualitatively normal ventricular function will suffice
- Patients who are sexually active and of reproductive potential must agree to use an acceptable form of highly effective contraception from consent to 12 months after BEAM 201 infusion; 4.2 Exclusion Criteria; Patients who meet any of the following criteria will be disqualified from entering the study:
- Active hepatitis B or active hepatitis C
- Active HTLV infection
- HIV infection
- Uncontrolled, active bacterial, viral, or fungal infection
- CNS disease that is progressive on therapy, or with CNS parenchymal lesions that might increase the risk of CNS toxicity
- Clinically active CNS dysfunction or known history of irreversible central neurological toxicity related to prior antileukemic therapy
- Receipt of prior CD7 targeted therapy
- Radiation therapy within 2 weeks prior to completion of screening, other than prophylaxis for CNS disease
- Acute GVHD that is grade ≥ 2 and requiring systemic immunosuppression (corticosteroids), or chronic GVHD that is mild, moderate, or severe and requiring systemic immunosuppression (corticosteroids). Grade 1 acute GVHD not requiring immunosuppression is allowable
- Undergone HSCT within 90 days prior to completion of screening (or donor leukocyte infusion, if received within 30 days prior to completion of screening)
- Any other condition that would make the patient ineligible for HSCT as determined by the investigator
- Known primary immunodeficiency or BM failure syndrome
- Atrial fibrillation/flutter (not including isolated episodes that responded to medical management)
- Clinically significant pericardial effusion
- Myocardial infarction within the last 12 months
- QT interval corrected for heart rate > 480 msec
- Cardiac dysfunction NYHA (New York Heart Association) III or IV
- Patients with an autoimmune disorder requiring systemic immunosuppressive therapy that cannot be safely withheld for 3 months; Concurrent use of systemic corticosteroids for diagnoses unrelated to T-ALL/T-LLy is prohibited, with exception of physiologic corticosteroid replacement therapy treatment for adrenal insufficiency
- Pregnant or breastfeeding
Where in United States
- Children's Hospital of PhiladelphiaPhiladelphia, United States
About the trial
What the trial wants to find out
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
The 2 groups in the trial
- Dose Escalation ArmTreatment being tested
The dose escalation portion of the trial will use a standard "3+3" design to establish the recommended maximum tolerated dose of BEAM-201 cells. Three dose escalations of BEAM-201 are planned for the dose escalation phase, with one dose de-escalation level if needed. Should there be sufficient clinical response at lower doses (i.e. DL1 or DL2), then the sponsor and principal investigator may choose to forgo further dose escalation and proceed to dose expansion at the lower dose level.
Treatment: Allogeneic anti-CD7 CAR-T cells (BEAM-201)
- Dose Expansion ArmTreatment being tested
If at least one dose level of the dose escalation phase is determined to be safe, the dose expansion phase of the trial will be opened to enrollment.
Treatment: Allogeneic anti-CD7 CAR-T cells (BEAM-201)
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1 Study of Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) or T-cell Lymphoblastic Lymphoma (T-LLy)
- Plain-language title
- Tests anti-CD7 CAR-T cells in T-cell leukemia or lymphoma that returnedGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 13 November 2026